Piramal Pharma Ltd (PPLPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003728,
    "name": "Piramal Pharma",
    "stock_name": "Piramal Pharma",
    "full_name": "Piramal Pharma Ltd",
    "name_url": "stocks-analysis/piramal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "161.20",
    "chg": 5.95,
    "chgp": "3.83%",
    "dir": 1,
    "prev_price": "155.25",
    "mcapval": "21,521.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543635,
    "symbol": "PPLPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0DK501011",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "40.95 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/piramal-pharma-1003728-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Piramal Pharma Stock Falls to 52-Week Low of Rs.180.1 Amidst Weak Financial Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-stock-hits-52-week-low-amidst-continued-downtrend-3746785",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/PiramalPharma_priceRelatedfactors_3746785.png",
        "date": "2025-12-04 12:49:17",
        "description": "Piramal Pharma’s shares touched a fresh 52-week low of Rs.180.1 today, marking a significant decline amid subdued financial performance and persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about profitability and debt servicing capacity."
      },
      {
        "title": "Is Piramal Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-piramal-pharma-technically-bullish-or-bearish-3745705",
        "imagepath": "",
        "date": "2025-12-04 08:48:43",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Shift and Momentum Indicators</strong></p>\n<p>As of 3 December 2025, Piramal Pharma's technical trend has shifted from mildly bearish to outright bearish. This change reflects a growing consensus among technical tools that the stock is facing sustained selling pressure. The Moving Average Convergence Divergence (MACD) indicator, a widely used momentum oscillator, shows a bearish signal on the weekly chart and remains mildly bearish on the monthly timeframe. This suggests that short-term momentum is weakening more sharply than longer-term trends, which still show some residual caution but no clear bullish reversal.</p>\n<p>The Relative Strength Index (RSI), often used to identify overbought or oversold conditions, currently provides no clear signal on either weekly or monthly c..."
      },
      {
        "title": "Piramal Pharma Technical Momentum Shifts Amid Bearish Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-technicals-turn-bearish-amid-steep-price-decline-3745546",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/PiramalPharma_technicaldot_3745546.png",
        "date": "2025-12-04 08:12:40",
        "description": "Piramal Pharma's stock price momentum has shifted towards a more bearish technical outlook, reflecting a series of signals from key indicators such as MACD, RSI, and moving averages. The pharmaceutical and biotechnology company’s recent price action and technical parameters suggest a cautious stance for investors amid broader market dynamics."
      },
      {
        "title": "How has been the historical performance of Piramal Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-piramal-pharma-3744786",
        "imagepath": "",
        "date": "2025-12-03 22:57:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the last four fiscal years, Piramal Pharma’s net sales have shown consistent growth, rising from ₹6,559 crore in March 2022 to ₹9,151 crore by March 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s expanding market presence and operational scale. Total operating income mirrored this trend, with no other operating income reported, indicating that core business activities have driven revenue growth.</p>\n<p>Operating profit before other income (PBDIT) exhibited volatility, with a dip in March 2023 to ₹628 crore from ₹950 crore in March 2022, before rebounding strongly to ₹1,445 crore in March 2025. The operating profit margin excluding other income improved from 14.48% in 2022 to 15...."
      },
      {
        "title": "Piramal Pharma Sees Revision in Market Evaluation Amidst Challenging Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-downgraded-to-strong-sell-by-marketsmojo-amid-weak-financials-3731545",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PiramalPharma_mojoScore_3731545.png",
        "date": "2025-11-26 09:46:59",
        "description": "Piramal Pharma has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. The changes stem from a combination of factors including its current financial performance, valuation metrics, and technical indicators, all of which have influenced investor sentiment in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Piramal Pharma Sees Revision in Market Evaluation Amidst Challenging Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-downgraded-to-strong-sell-by-marketsmojo-amid-weak-financials-3730699",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PiramalPharma_mojoScore_3730699.png",
        "date": "2025-11-26 09:46:59",
        "description": "Piramal Pharma has undergone a revision in its market evaluation reflecting recent developments in its financial and technical parameters. The pharmaceutical company’s assessment now indicates a more cautious outlook, driven by a combination of valuation concerns, financial trends, and technical indicators."
      },
      {
        "title": "Why is Piramal Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-piramal-pharma-fallingrising-3730037",
        "imagepath": "",
        "date": "2025-11-26 01:30:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Position</strong></p>\n<p>Piramal Pharma’s shares have been under pressure, falling 3.67% over the past week and 8.53% in the last month, significantly underperforming the Sensex benchmark, which has remained relatively flat or positive during these periods. Year-to-date, the stock has plunged over 30%, contrasting sharply with the Sensex’s 8.25% gain. Even over the past year, the stock has declined by nearly 26%, while the broader market has advanced by 5.59%. Despite this, the company’s three-year returns remain positive at 41.75%, slightly ahead of the Sensex’s 35.79%, indicating some resilience over a longer horizon.</p>\n<p>On 25-Nov, the stock traded close to its 52-week low, just 2.51% above the lowest price of ₹180.35, signalling sustained weakness. ..."
      },
      {
        "title": "How has been the historical performance of Piramal Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-piramal-pharma-3677378",
        "imagepath": "",
        "date": "2025-11-06 23:04:33",
        "description": "Answer:\nThe historical performance of Piramal Pharma shows a fluctuating trend in key financial metrics over the past four years.\n\nBreakdown:\nPiramal Pharma's net sales have consistently increased from INR 6,559.10 crore in March 2022 to INR 9,151.18 crore in March 2025. Total operating income followed a similar upward trajectory, reaching INR 9,151.18 crore in March 2025, up from INR 6,559.10 crore in March 2022. However, total expenditure also rose significantly, from INR 5,609.44 crore in March 2022 to INR 7,706.35 crore in March 2025. Operating profit (PBDIT) improved from INR 1,225.46 crore in March 2022 to INR 1,579.64 crore in March 2025, indicating a recovery in profitability, despite a dip in profit before tax in March 2023 to -INR 174.48 crore. The profit after tax showed a notable recovery, moving from a loss of INR 240.79 crore in March 2023 to a profit of INR 18.20 crore in March 2025. The comp..."
      },
      {
        "title": "Piramal Pharma Q2 FY26: Losses Deepen Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/piramal-pharma-q2-fy26-losses-deepen-amid-margin-pressures-3676475",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PiramalPharma_quaterlyResult_3676475.png",
        "date": "2025-11-06 09:57:55",
        "description": "Piramal Pharma Ltd. reported a consolidated net loss of ₹99.22 crores for Q2 FY26, marking a significant deterioration from the ₹22.59 crores profit posted in the year-ago quarter. The pharmaceutical company, with a market capitalisation of ₹27,269.53 crores, saw its operating margins compress sharply to 7.76% from 15.24% in Q2 FY25, reflecting mounting operational challenges. The stock traded at ₹205.15 on November 6, down 30.11% over the past year, substantially underperforming both the broader market and the pharmaceuticals sector."
      }
    ],
    "total": 344,
    "sid": "1003728",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/piramal-pharma-1003728"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "30-Jan-2026",
      "details": "Please see enclosed Transcript of Conference Call on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Results - Financial Results For The Quarter Ended December 31 2025",
      "datetime": "29-Jan-2026",
      "details": "Please find enclosed Unaudited Financial Results (Standalone & Consolidated) for quarter ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer",
      "datetime": "29-Jan-2026",
      "details": "Please refer attached file",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Piramal Pharma Ltd has declared <strong>1%</strong> dividend, ex-date: 16 Jul 25",
          "dt": "2025-07-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Piramal Pharma Ltd has announced <strong>5:46</strong> rights issue, ex-date: 02 Aug 23",
          "dt": "2023-08-02",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Piramal Pharma Stock Falls to 52-Week Low of Rs.180.1 Amidst Weak Financial Indicators

2025-12-04 12:49:17

Piramal Pharma’s shares touched a fresh 52-week low of Rs.180.1 today, marking a significant decline amid subdued financial performance and persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about profitability and debt servicing capacity.

Is Piramal Pharma technically bullish or bearish?

2025-12-04 08:48:43

Technical Trend Shift and Momentum Indicators As of 3 December 2025, Piramal Pharma's technical trend has shifted from mildly bearish to outright bearish. This change reflects a growing consensus among technical tools that the stock is facing sustained selling pressure. The Moving Average Convergence Divergence (MACD) indicator, a widely used momentum oscillator, shows a bearish signal on the weekly chart and remains mildly bearish on the monthly timeframe. This suggests that short-term momentum is weakening more sharply than longer-term trends, which still show some residual caution but no clear bullish reversal. The Relative Strength Index (RSI), often used to identify overbought or oversold conditions, currently provides no clear signal on either weekly or monthly c...

Piramal Pharma Technical Momentum Shifts Amid Bearish Indicators

2025-12-04 08:12:40

Piramal Pharma's stock price momentum has shifted towards a more bearish technical outlook, reflecting a series of signals from key indicators such as MACD, RSI, and moving averages. The pharmaceutical and biotechnology company’s recent price action and technical parameters suggest a cautious stance for investors amid broader market dynamics.

How has been the historical performance of Piramal Pharma?

2025-12-03 22:57:29

Revenue and Profitability Trends Over the last four fiscal years, Piramal Pharma’s net sales have shown consistent growth, rising from ₹6,559 crore in March 2022 to ₹9,151 crore by March 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s expanding market presence and operational scale. Total operating income mirrored this trend, with no other operating income reported, indicating that core business activities have driven revenue growth. Operating profit before other income (PBDIT) exhibited volatility, with a dip in March 2023 to ₹628 crore from ₹950 crore in March 2022, before rebounding strongly to ₹1,445 crore in March 2025. The operating profit margin excluding other income improved from 14.48% in 2022 to 15....

Piramal Pharma Sees Revision in Market Evaluation Amidst Challenging Financials

2025-11-26 09:46:59

Piramal Pharma has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. The changes stem from a combination of factors including its current financial performance, valuation metrics, and technical indicators, all of which have influenced investor sentiment in the Pharmaceuticals & Biotechnology sector.

Piramal Pharma Sees Revision in Market Evaluation Amidst Challenging Financials

2025-11-26 09:46:59

Piramal Pharma has undergone a revision in its market evaluation reflecting recent developments in its financial and technical parameters. The pharmaceutical company’s assessment now indicates a more cautious outlook, driven by a combination of valuation concerns, financial trends, and technical indicators.

Why is Piramal Pharma falling/rising?

2025-11-26 01:30:06

Recent Price Performance and Market Position Piramal Pharma’s shares have been under pressure, falling 3.67% over the past week and 8.53% in the last month, significantly underperforming the Sensex benchmark, which has remained relatively flat or positive during these periods. Year-to-date, the stock has plunged over 30%, contrasting sharply with the Sensex’s 8.25% gain. Even over the past year, the stock has declined by nearly 26%, while the broader market has advanced by 5.59%. Despite this, the company’s three-year returns remain positive at 41.75%, slightly ahead of the Sensex’s 35.79%, indicating some resilience over a longer horizon. On 25-Nov, the stock traded close to its 52-week low, just 2.51% above the lowest price of ₹180.35, signalling sustained weakness. ...

How has been the historical performance of Piramal Pharma?

2025-11-06 23:04:33

Answer: The historical performance of Piramal Pharma shows a fluctuating trend in key financial metrics over the past four years. Breakdown: Piramal Pharma's net sales have consistently increased from INR 6,559.10 crore in March 2022 to INR 9,151.18 crore in March 2025. Total operating income followed a similar upward trajectory, reaching INR 9,151.18 crore in March 2025, up from INR 6,559.10 crore in March 2022. However, total expenditure also rose significantly, from INR 5,609.44 crore in March 2022 to INR 7,706.35 crore in March 2025. Operating profit (PBDIT) improved from INR 1,225.46 crore in March 2022 to INR 1,579.64 crore in March 2025, indicating a recovery in profitability, despite a dip in profit before tax in March 2023 to -INR 174.48 crore. The profit after tax showed a notable recovery, moving from a loss of INR 240.79 crore in March 2023 to a profit of INR 18.20 crore in March 2025. The comp...

Piramal Pharma Q2 FY26: Losses Deepen Amid Margin Pressures

2025-11-06 09:57:55

Piramal Pharma Ltd. reported a consolidated net loss of ₹99.22 crores for Q2 FY26, marking a significant deterioration from the ₹22.59 crores profit posted in the year-ago quarter. The pharmaceutical company, with a market capitalisation of ₹27,269.53 crores, saw its operating margins compress sharply to 7.76% from 15.24% in Q2 FY25, reflecting mounting operational challenges. The stock traded at ₹205.15 on November 6, down 30.11% over the past year, substantially underperforming both the broader market and the pharmaceuticals sector.

View All News